PL402550A1 - Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika - Google Patents

Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika

Info

Publication number
PL402550A1
PL402550A1 PL402550A PL40255002A PL402550A1 PL 402550 A1 PL402550 A1 PL 402550A1 PL 402550 A PL402550 A PL 402550A PL 40255002 A PL40255002 A PL 40255002A PL 402550 A1 PL402550 A1 PL 402550A1
Authority
PL
Poland
Prior art keywords
peroxide source
pharmaceutical composition
bioadhesive
bioadhesive carrier
peroxide
Prior art date
Application number
PL402550A
Other languages
English (en)
Polish (pl)
Inventor
William J. Bologna
Howard L. Levine
Original Assignee
Columbia Laboratories (Bermuda) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Laboratories (Bermuda) Limited filed Critical Columbia Laboratories (Bermuda) Limited
Publication of PL402550A1 publication Critical patent/PL402550A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL402550A 2001-10-29 2002-10-28 Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika PL402550A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33068301P 2001-10-29 2001-10-29
US10/278,910 US7709026B2 (en) 2001-10-29 2002-10-24 Low concentration of peroxide for treating or preventing vaginal infections

Publications (1)

Publication Number Publication Date
PL402550A1 true PL402550A1 (pl) 2013-08-05

Family

ID=26959335

Family Applications (2)

Application Number Title Priority Date Filing Date
PL402550A PL402550A1 (pl) 2001-10-29 2002-10-28 Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
PL369725A PL216746B1 (pl) 2001-10-29 2002-10-28 Dopochwowa kompozycja farmaceutyczna i zastosowanie źródła nadtlenku oraz polikarbofilu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL369725A PL216746B1 (pl) 2001-10-29 2002-10-28 Dopochwowa kompozycja farmaceutyczna i zastosowanie źródła nadtlenku oraz polikarbofilu

Country Status (30)

Country Link
US (1) US7709026B2 (cg-RX-API-DMAC7.html)
EP (1) EP1441769B1 (cg-RX-API-DMAC7.html)
JP (2) JP5153049B2 (cg-RX-API-DMAC7.html)
KR (1) KR101009146B1 (cg-RX-API-DMAC7.html)
CN (1) CN1578676A (cg-RX-API-DMAC7.html)
AR (1) AR037047A1 (cg-RX-API-DMAC7.html)
AT (1) ATE297222T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002346897B2 (cg-RX-API-DMAC7.html)
BR (1) BR0213584A (cg-RX-API-DMAC7.html)
CA (1) CA2465133C (cg-RX-API-DMAC7.html)
DE (1) DE60204584T2 (cg-RX-API-DMAC7.html)
DK (1) DK1441769T3 (cg-RX-API-DMAC7.html)
ES (1) ES2243772T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20040480B1 (cg-RX-API-DMAC7.html)
HU (1) HU229487B1 (cg-RX-API-DMAC7.html)
IL (2) IL161512A0 (cg-RX-API-DMAC7.html)
MA (1) MA26289A1 (cg-RX-API-DMAC7.html)
ME (1) MEP34608A (cg-RX-API-DMAC7.html)
MX (1) MXPA04003977A (cg-RX-API-DMAC7.html)
MY (1) MY137791A (cg-RX-API-DMAC7.html)
NO (1) NO20042199L (cg-RX-API-DMAC7.html)
NZ (1) NZ532294A (cg-RX-API-DMAC7.html)
PE (1) PE20030492A1 (cg-RX-API-DMAC7.html)
PL (2) PL402550A1 (cg-RX-API-DMAC7.html)
PT (1) PT1441769E (cg-RX-API-DMAC7.html)
RS (1) RS51154B (cg-RX-API-DMAC7.html)
RU (1) RU2329829C2 (cg-RX-API-DMAC7.html)
SI (1) SI1441769T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003037382A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200402943B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
CH697081A5 (de) * 2002-01-22 2008-04-30 Andreas F Dr Schaub Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten.
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
DE10328942A1 (de) * 2003-06-27 2005-01-27 Lts Lohmann Therapie-Systeme Ag Transmukosale Darreichungsformen mit verminderter Schleimhautirritation
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
US20050276865A1 (en) * 2004-05-20 2005-12-15 Servet Buyuktimkin Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
DE102004054552A1 (de) * 2004-11-11 2006-05-18 Hcb Happy Child Birth Holding Ag Neue Zusammensetzung zur Erleichterung der Humangeburt
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US20120074014A1 (en) * 2010-09-27 2012-03-29 Lutran Industries, Inc. Product typically based on salt of peroxymonosulfuric acid and suitable for medicinal usage, and associated product fabrication
US9895311B2 (en) 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
US20180280340A1 (en) * 2017-03-30 2018-10-04 Konstantin Zubovskiy Method of treating and preventing infections
CN110785163B (zh) 2017-05-23 2023-09-05 法尔米瓦股份公司 用于递送活性剂至体腔的泡沫形成组合物
AU2019365255B2 (en) * 2018-10-26 2025-06-12 Viramal Limited Mucoadhesive gel composition
US11850303B2 (en) * 2020-10-27 2023-12-26 Uqora, Inc. Gel and a suppository and methods to provide the gel and suppository
WO2024231498A1 (en) * 2023-05-09 2024-11-14 BioNTech SE Intravaginal formulations of gardnerella endolysins
TW202541833A (zh) * 2023-12-12 2025-11-01 德商拜恩技術股份公司 包含內溶素之組合物及其用途
WO2025217642A1 (en) * 2024-04-12 2025-10-16 The General Hospital Corporation System and method of treating vaginal infections and inflammation

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
BE535125A (cg-RX-API-DMAC7.html) 1954-01-25
NL108604C (cg-RX-API-DMAC7.html) 1957-08-27
US4127515A (en) * 1974-10-21 1978-11-28 Colgate-Palmolive Company Waxing sponge
US4607101A (en) * 1981-08-27 1986-08-19 Jaye-Boern Laboratories, Inc. Method of treating acne vulgaris with a composition containing carbamide peroxide
JPH0830004B2 (ja) * 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
GB8505402D0 (en) * 1985-03-02 1985-04-03 Ciba Geigy Ag Modified phenolic resins
US4657935A (en) * 1985-07-22 1987-04-14 Carlos Teplicki Real acne control (RAC)
US4923677A (en) 1985-08-07 1990-05-08 Roy T. Witkin Chemical sterilization
US4997625A (en) 1985-08-07 1991-03-05 Simon Gilbert I Chemical sterilization
US4670256A (en) 1985-09-23 1987-06-02 V. Valhalla Corp. Vaginal conditioning for sexual activity
US4781923A (en) * 1987-07-20 1988-11-01 Pellico Michael A Antiseptic gels
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US6017521A (en) * 1989-10-31 2000-01-25 Columbia Laboratories, Inc. Use of polycarboxylic acid polymers to treat vaginal infections
US5376006A (en) 1990-03-22 1994-12-27 Ultradent Products, Inc. Dental bleaching compositions and methods for bleaching teeth surfaces
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5573765A (en) 1991-02-19 1996-11-12 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
US5340836A (en) 1991-02-19 1994-08-23 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
IL97930A (en) * 1991-04-23 1996-06-18 Perio Prod Ltd Preparations for whitening two controlled release products that contain a super-oxygen compound
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
US5667817A (en) 1992-03-20 1997-09-16 Alcide Corporation Method and composition for prevention and treatment of female lower genital tract microbial infections
US5898037A (en) 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5489435A (en) 1993-07-06 1996-02-06 Ratcliff; Perry A. Composition for treatment of abnormal conditions of the epithelium of bodily orifices
US6200557B1 (en) 1993-07-06 2001-03-13 Perry A. Ratcliff Method of treating HIV by a topical composition
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
UA39965C2 (uk) 1993-12-03 2001-07-16 Лайфор Леборетріз Лтд Вірусоцидний, бактерицидний та руйнуючий сперматозоїди вагінальний засіб і вагінальний супозиторій ( варіанти )
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US5741525A (en) * 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
PT869772E (pt) * 1995-12-27 2002-03-28 Janssen Pharmaceutica Nv Forma galenica solida bioadesiva
US5778886A (en) 1996-02-27 1998-07-14 Shihata; Alfred Vaginal compositions combining a spermicidal agent and a peroxygen compound
US5819742A (en) 1996-11-06 1998-10-13 Family Health International Vaginal device for preventing conception or the transmission of sexually transmitted diseases, or both
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
US5843998A (en) * 1997-06-30 1998-12-01 Song; Jin Skin blemish treatment
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6117859A (en) * 1997-11-04 2000-09-12 The Research Foundation Of State University Of New York Method of relieving chronic inflammation by using 5-alkylsulfonylsalicylanilides
JP2002518351A (ja) 1998-06-19 2002-06-25 オキシバイオ・インコーポレイテッド 抗感染および避妊特性を有する医療装置
US6277363B1 (en) 1998-09-21 2001-08-21 Vortech, Inc. Method and composition for treating chlamydia infection
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
EP1267826B1 (en) 1999-10-22 2007-01-03 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
US6200551B1 (en) 2000-01-27 2001-03-13 Susan Ann Morgan Treatment for dry mouth employing carbamide peroxide
US6235314B1 (en) * 2000-08-08 2001-05-22 Sarfaraz K. Niazi Analgesic, anti-inflammatory and skeletal muscle relaxant compositions
JP4086658B2 (ja) * 2000-10-02 2008-05-14 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗菌薬および抗炎症剤としてのナフチルサリチルアニリド
US20030211173A1 (en) 2002-05-08 2003-11-13 Veach Tom C. Lubrication composition
US7049000B2 (en) * 2003-08-06 2006-05-23 The Procter & Gamble Company Water-swellable material comprising coated water-swellable polymers
US20090156672A1 (en) * 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities

Also Published As

Publication number Publication date
EP1441769A1 (en) 2004-08-04
AR037047A1 (es) 2004-10-20
ZA200402943B (en) 2005-03-30
NZ532294A (en) 2006-12-22
CA2465133C (en) 2012-03-06
MXPA04003977A (es) 2004-07-08
RS36604A (sr) 2006-12-15
HUP0401672A2 (hu) 2005-07-28
RU2329829C2 (ru) 2008-07-27
NO20042199L (no) 2004-05-26
CA2465133A1 (en) 2003-05-08
HU229487B1 (en) 2014-01-28
HRP20040480A2 (en) 2004-10-31
HUP0401672A3 (en) 2008-04-28
BR0213584A (pt) 2004-08-24
JP2010248232A (ja) 2010-11-04
CN1578676A (zh) 2005-02-09
PT1441769E (pt) 2005-08-31
KR20050056903A (ko) 2005-06-16
SI1441769T1 (sl) 2005-12-31
PL216746B1 (pl) 2014-05-30
JP2005510505A (ja) 2005-04-21
PE20030492A1 (es) 2003-06-16
DK1441769T3 (da) 2005-09-12
KR101009146B1 (ko) 2011-01-18
IL161512A0 (en) 2004-09-27
MEP34608A (en) 2011-02-10
WO2003037382A1 (en) 2003-05-08
HRP20040480B1 (hr) 2007-11-30
MA26289A1 (fr) 2004-09-01
EP1441769B1 (en) 2005-06-08
DE60204584T2 (de) 2006-03-16
RS51154B (sr) 2010-10-31
AU2002346897B2 (en) 2008-04-17
RU2004116312A (ru) 2005-04-10
DE60204584D1 (de) 2005-07-14
PL369725A1 (en) 2005-05-02
MY137791A (en) 2009-03-31
JP5153049B2 (ja) 2013-02-27
US20030091644A1 (en) 2003-05-15
ES2243772T3 (es) 2005-12-01
HK1063290A1 (en) 2004-12-24
IL161512A (en) 2009-07-20
ATE297222T1 (de) 2005-06-15
US7709026B2 (en) 2010-05-04

Similar Documents

Publication Publication Date Title
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
MY129356A (en) Electrospun pharmaceutical compositions
SE0102315D0 (sv) Compounds
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
DE60212847D1 (de) Topisch anwendbare arzneimittelformulierung
HRP20040480B1 (hr) Niska koncentracija peroksida za tretman i prevenciju vaginalnih infekcija
PL373276A1 (en) Trans-epicutaneous administration form for treating restless leg syndrome
UA90077C2 (uk) Антидисритмічні агенти для лікування тазового болю, що призначаються вагінально
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
AU2357202A (en) Ion-strength independent sustained release pharmaceutical formulation
PT1414467E (pt) Tratamento topico da mastalgia
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
MXPA03010672A (es) Composicion para el tratamiento regenerativo de enfermedades del cartilago.
SE0001916D0 (sv) Novel formulation
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
SE0102887D0 (sv) New formulation
BR0113055A (pt) Preparação sólida altamente absorvìvel
MXPA04011560A (es) Formulacion anti-cancer.
UA90076C2 (ru) Низкоконцентрированный пероксид для лечения или профилактики вагинальных заражений
ATE533480T1 (de) Zusammensetzung zur behandlung von hämorrhoiden
BG106430A (en) Liquid mucoadhesive pharmaceutical composition
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)